High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia
NCT01205035
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
6
Enrollment
OTHER
Sponsor class
Conditions
Retinal Diseases
Telangiectasis
Interventions
DRUG:
ranibizumab 2.0mg
Sponsor
Eye Center of Northern Colorado, P.C.
Collaborators
[object Object]